We believe this issue has no bearing on our proposed acquisition of Guidant. Unfortunately, threats of legal action are commonplace in our industry. |
We believe we can close by the end of March. |
We continue to believe our $72 (a share) proposal is better for Guidant, its shareholders and its employees than Johnson & Johnson's revised offer. We are offering significantly more value, and there is strong upside potential over time. |
We continue to believe our $72 (per share) proposal is better for Guidant, its shareholders and its employees than Johnson & Johnson's revised offer. We are offering significantly more value, and there is strong upside potential over time. We continue to move forward on our due diligence with the goal of reaching a definitive agreement with Guidant. |
We continue to believe our $72 proposal is better for Guidant, its shareholders and its employees than Johnson & Johnson's revised offer. We are offering significantly more value, and there is strong upside potential over time. We continue to move forward on our due diligence with the goal of reaching a definitive agreement with Guidant. |
We continue to expect to be in a position to sign a definitive agreement in the first two weeks of January. |
We continue to move forward on our due diligence with the goal of reaching a definitive agreement with Guidant. |
We continue to move forward on our due diligence with the goal of reaching a definitive agreement with Guidant. I don't think we're going to have anything more to say right now. |
We continue to move forward with our due diligence with the goal of reaching a definitive agreement with Guidant. |
We factored in the possibility of something like this happening. This news is manageable and does not alter our fundamental belief in Guidant's long-term potential, which is significant and very much intact. |
We have brought a lot of companies into the Boston Scientific family and we have never been more confident or enthusiastic about the prospects for a merger. |
We should have things re-stocked in a few weeks. |
We will recommend changes designed to ensure that the final regulation preserves the fullest possible beneficiary access to innovative technologies and therapies. |
We're pleased to close this chapter, and put this matter behind us. We can now direct our full attention to developing our life-saving products and technologies. |
We've reviewed the intellectual property issues and are comfortable proceeding with the transaction. We don't expect this issue to impact the transaction. |